

it is yet to be clarified whether CD16<sup>+</sup> monocytes are differentiated from CD16<sup>-</sup> monocytes or not.

Multiple factors are reported to enhance CD16 expression on monocytes, such as

macrophage-colony-stimulating factor (M-CSF), IL-10 and transforming growth factor (TGF)- $\beta$ 1

(23). In addition, some studies disclosed that hypoxia and MIF contributed to TIE2 expression on

monocytes in vitro (14, 24). Cumulative data have been published showing that cancer cells,

including HCC, are dichotomously capable of releasing various inflammatory (TNF- $\alpha$ , IL-1 $\beta$ ) and

anti-inflammatory (TGF- $\beta$  and IL-10) cytokines, as well as hematopoietic factors (M-CSF and MIF)

(7, 25-29). However, in this study, no correlation was found between the frequency of TEMs and any

of serum angiogenesis factors (Supplementary figure 3). It is thus plausible that, not a sole but a

mixture of such HCC-derived factors contributes to the generation of TEMs from CD16<sup>+</sup> monocytes

with the aid of a hypoxic microenvironment. In our preliminary study, a combination of cytokines

and growth factors were able to induce TIE2 on CD16<sup>+</sup> monocytes (manuscript in preparation).

Although the presence of TEMs has been reported in cancer tissues from patients with colorectal,

pancreatic or renal cancer (15), the actual roles of TEMs in the angiogenesis process of HCC have

yet to be elucidated. In this study, we showed that the peripheral and intrahepatic frequency of TEMs

is positively correlated with the density of micro-vessels in the liver. Additionally, we found that

TEMs accumulate in the liver and are located in the perivascular area of HCC tissues. In support for

our observations, Venneri et al. reported that TEMs preferentially localize in the vicinity of tumor

Accepted Article

blood vessels and avascular viable areas in human cancer specimens but are not found in non-neoplastic tissues adjacent to tumors (15). These results suggest that TEMs may take some part in HCC-related vascular formation. Further investigation is still needed to disclose the molecular mechanisms of TEMs accumulating in the liver. In analogy of CD14<sup>+</sup>CD16<sup>+</sup> monocytes, some interactions between chemokine and its receptors, such as CCR5 or CX3CR1, may be involved in such process (22), all of which are shown to be expressed in TEMs as well (Fig. 1D).

Thus far, many studies have reported that the histological degree of angiogenesis in the liver is closely correlated with the prognosis or survival of patients with HCC. In agreement with these results, several serum angiogenesis factors, such as VEGF, ANG-2, sVEGFR-1 and MIF, are reported to be feasible as markers of prognosis, invasiveness or post-therapeutic recurrence in HCC patients (7-11). Multivariate analysis disclosed that the degree of angiogenesis in the liver, as assessed by MVD, is an independent factor significantly involved in the disease-free survival rate in patients with resectable HCC (17). Therefore, the positive correlation between peripheral and intra-hepatic TEM frequency and MVD in the liver observed in this study offers the possibility of TEMs being as a prognostic marker of HCC patients. In support for this, the patients with higher TEM frequency were at a more advanced Child-Pugh stage, had poorer liver function and showed higher post-therapeutic HCC recurrence in this cohort.

In order to diagnose the existence of HCC, serum AFP and PIVKA-II levels have been commonly used in clinical practice. However, the sensitivity and specificity of both markers are unsatisfactory for the detection of HCC (12). In the present study, in differentiating HCC from CLD or LC, ROC analysis revealed that the peripheral frequency of TEMs is higher than serum AFP, PIVKA-II, ANG-2 levels with respect to AUC, sensitivity and specificity. Thus, the frequency of TEMs could be better than AFP and PIVKA-II for diagnosing HCC. Evaluation of the clinical value of TEMs in the long-term prognosis of HCC patients is further needed as the observation periods in the current study were a maximum of 3.0 years. During the observation period, no significant difference was detected in such outcome between the TEM<sup>high</sup> and TEM<sup>low</sup> groups (Supplementary figure 2).

In summary, TEMs are significantly increased both in the periphery and in the liver of HCC patients and hold diagnostic value for HCC. The frequency of TEMs is well correlated with the degrees of neo-vascularization in HCC tissue. Thus, TEMs would be feasible as a diagnostic cellular marker of HCC potentially reflecting angiogenesis in the liver.

**Figure Legends**

**Fig. 1: Identification and phenotypic analyses of TEMs as CD14<sup>+</sup>CD16<sup>+</sup>TIE2<sup>+</sup> cells in the peripheral blood.**

**A.** PBMC obtained from HCC patients were stained and analyzed by flow cytometry. CD14<sup>+</sup> monocytes were divided into two distinct subsets, CD14<sup>++</sup>CD16<sup>-</sup> and CD14<sup>+</sup>CD16<sup>+</sup> cells. These cells were examined for TIE2 expression. The numbers in the histograms depict the percentages of gated cells. Representative plots from three patients are shown.

**B.** Frequencies of TIE2 in CD14<sup>+</sup> monocytes were compared among two distinct subsets; CD16<sup>+</sup> monocytes and CD16<sup>-</sup> monocytes, See Fig.1A. The bars indicate mean  $\pm$  SE of 89 patients. \*:  $p < 0.0001$  by Mann-Whitney nonparametric U test.

**C.** Western-blot analysis of TIE2 expression in FACS-sorted CD14<sup>+</sup>CD16<sup>+</sup> and CD14<sup>++</sup>CD16<sup>-</sup> cells from HCC patients. As shown, the bands were TIE2 (140 kDa molecular weight) (the top panels) and those are  $\beta$ -actin (45 kDa molecular weight) (the bottom panels), respectively. The representative results of three series of experiments from 7 HCC patients are shown.

**D.** TEMs and TIE2<sup>-</sup> monocytes in the periphery were gated and analyzed for the expression of various molecules, as indicated in the histogram plots. The filled light gray line, black line and gray line depict the negative control, the expression of relevant markers in TEMs and TIE2<sup>-</sup> monocytes,

respectively. The percentage of the marker-positive cells is shown in the histograms. The upper numbers are for TEMs and the lower ones are for TIE2<sup>+</sup> monocytes. The representative plots of six series of experiments are shown.

E. Comparative analyses of the expression of CCR4, CCR5, CX3CR1, CD40 and CD86 between TEMs and TIE2<sup>+</sup> monocytes, assessed by FACS as described above. The bars indicate mean  $\pm$  SE of six series of experiments. \*:  $p < 0.05$ , \*\*:  $p < 0.005$ , \*\*\*:  $p < 0.001$  by Mann-Whitney non-parametric U test.

**Fig. 2: Peripheral frequency of TEMs is increased in patients with HCC, with changes paralleling post therapeutic HCC recurrence.**

A. Frequencies of peripheral TEMs in CD14<sup>+</sup> monocytes are shown in four groups of HCV-positive patients; HS, CH, LC and HCC, see Table.1. \*:  $p < 0.0001$  by Kruskal-Wallis test with Dunn's multiple comparison test.

B. Frequencies of peripheral TEMs in HCC patients at different clinical TNM stages (early stage; I-II; n=70, advanced stage; III-IV; n=19). n.s., not significant by Mann-Whitney nonparametric U test.

C. In patients who underwent RFA therapy or resection of HCC, the frequencies of TEMs in CD14<sup>+</sup> monocytes were examined serially after confirmation of complete ablation or operation to remove

HCC lesions. The bold arrows depict the time point of the RFA therapy or the operation. Both panels depict the frequencies of TEMs in patients before and after the treatment. The left panel shows the results of TEMs in patients without HCC recurrence (n=12) as assessed by CT/MRI examinations, while the right panel shows the results in patients with HCC recurrence (n=5), respectively. \*: p<0.05 by Paired t-test.

**D.** In patients with HCC who underwent RFA or the operation, the recurrence-free survival rate after the treatment was compared between those with TEM<sup>high</sup> (frequency of TEMs  $\geq$  2.75; n=45) and TEM<sup>low</sup> (frequency of TEMs < 2.75; n=44) using the Kaplan-Meier method, with the log-rank test for comparison. TEM<sup>high</sup> and TEM<sup>low</sup>, see Table 2. p = 0.047.

**Fig. 3: TEMs are observed in perivascular areas of HCC tissue, and their frequency is higher in HCC tissue than in the periphery.**

**A.** Immunofluorescence staining was performed as described in Materials and Methods. The staining for CD14 (green), CD16 (red) and TIE2 (red) identifies CD14<sup>+</sup>TIE2<sup>-</sup>, CD14<sup>+</sup>TIE2<sup>+</sup>, CD14<sup>+</sup>CD16<sup>-</sup> cells and CD14<sup>+</sup>CD16<sup>+</sup> monocytes in human liver tissue (blue: nuclei counterstained with Dapi).

Representative results of the resected samples obtained from 12 HCC patients are shown. The panels show CD14<sup>+</sup>TIE2<sup>+</sup> cells (A, B, D) and CD14<sup>+</sup>CD16<sup>+</sup> cells (C) in the perivascular area of HCC tissue (magnification, 400 $\times$ ), Bold arrows depict CD14<sup>+</sup>TIE2<sup>+</sup> cells, thin arrows CD14<sup>+</sup>CD16<sup>+</sup> cells, bold

arrowheads vascular endothelial cells (TIE2<sup>+</sup>CD14<sup>-</sup>) and thin arrowheads CD14<sup>+</sup>TIE2<sup>-</sup> cells.

B. The frequencies of TEMs in 9 patients with HCC are compared for those in the peripheral blood or in the liver. Liver-infiltrating leukocytes are divided into two distinct groups: leukocytes infiltrating non-tumor tissue (NIL) and tumor-infiltrating leukocytes (TIL). These cells were stained using anti-human CD14, CD16 and TIE2 mAbs. The analyses were performed as described in Materials and Methods. The samples were obtained from nine patients who underwent tumor resection. \*: p<0.05, \*\*: p<0.0005, by Paired t-test.

C. The correlation is analyzed between the frequencies of TEMs in PBMC and those in tumor-infiltrated lymphocytes. Analysis (n=14) was based on Pearson's correlation coefficient. P = 0.003, R<sup>2</sup> = 0.53

**Fig 4: The degree of microvessels in HCC is correlated with the frequency of TEMs**

A. Assessment of neo-vascularization in HCC tissue was performed by staining CD34<sup>+</sup> cells in the resected samples obtained from patients with HCC. Immunohistochemical staining for CD34 was done as described in Materials and Methods. The CD34<sup>+</sup> cells were mainly confined to the cytoplasm of vascular endothelial cells as brownish yellow granules. Microvessels were represented by brownish yellow capillaries or small cell clusters. Representative results are shown. The panel shows a tumor cell area of a high grade.

**B.** The correlation is analyzed between TEM frequencies and the counts of CD34<sup>+</sup> cells (MVD values) in relevant patients. The panels show the correlation of peripheral (left: n=11) or intra-tumoral TEM frequencies (right: n=9) and MVD ( $p = 0.0009$ ,  $R^2 = 0.72$  and  $p = 0.04$ ,  $R^2 = 0.44$ , respectively). Analysis was based on Pearson's correlation coefficient.

**Fig. 5: Frequency of TEMs is superior as a diagnostic for HCC to common tumor markers or angiogenesis factor.**

**A.** Correlation between TEM frequency and AFP (n=87) or PIVKA-II (n=81) was analyzed using Pearson's correlation coefficient.  $P = 0.45$ ,  $R^2 = 0.007$  or  $P = 0.27$ ,  $R^2 = 0.02$ , respectively.

**B.** ROC analyses were performed in order to assess the diagnostic value of TEM frequency for differentiating HCC (n=89) from chronic liver disease (CLD, n=79) or liver cirrhosis (LC, n=30).

The left panel shows the diagnostic value of TEMs, PIVKA-II, AFP and angiopoietin-2 (ANG-2) for HCC from CLD and the right panel shows those for HCC from LC, respectively.

**Supplementary figure 1: Frequency of TEMs is comparable in HCC patients regardless of etiology.**

The frequencies of peripheral TEMs are shown for HCC patients with or without HCV infection (n=89 and n=26, respectively). The group without HCV infection included patients with HBV



infection or those without HBV nor HCV (HBV-HCC and Non-B, Non-C [NBNC] HCC patients).

n.s. not significant by Mann-Whitney non-parametric U test.

**Supplementary figure 2: Peripheral frequency of TEMs is not related to the overall survival in patients with HCC.**

In patients with HCC who underwent RFA or the operation, the overall survival rate after the treatment was compared between those with TEM<sup>high</sup> (frequency of TEMs  $\geq$  2.75; n=45) and TEM<sup>low</sup> (frequency of TEMs < 2.75; n=44) using the Kaplan-Meier method, with the log-rank test for comparison. TEM<sup>high</sup> and TEM<sup>low</sup>, see Table 2. P=0.36

**Supplementary figure 3: Correlation between the frequency of TEMs and serum levels of angiogenesis factors**

All plots indicate the correlation between TEM frequency and VEGF, ANG-2, sVEGFR-1 or MIF.

The numbers of patients examined were 32, 37, 23 and 31, respectively. Analyses were based on

Pearson's correlation coefficient.

Accepted Article

#### Acknowledgements

We are grateful to Wei Li for her exceptional assistance for experiments (Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine).

## References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001;94:153-156.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology* 2004;127:S27-34.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;362:1907-1917.
4. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. *Nat Rev Cancer* 2008;8:618-631.
5. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. *Hepatology* 1998;27:1554-1562.
6. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. *Liver Int* 2011;31:146-162.
7. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, Nagasue N. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. *Cancer* 2005;103:588-598.
8. Kuboki S, Shimizu H, Mitsuhashi N, Kusashio K, Kimura F, Yoshidome H, Ohtsuka M, et al. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma. *J Gastroenterol Hepatol* 2008;23:e157-164.
9. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Hisamoto T, Yoshida Y, Abe M, et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. *Oncol Rep* 2010;23:1647-1654.
10. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. *Br J Cancer* 2009;100:1385-1392.
11. Tamesa T, Iizuka N, Mori N, Okada T, Takemoto N, Tangoku A, Oka M. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. *Hepatogastroenterology* 2009;56:1122-1126.

12. Yuen MF, Lai CL. Serological markers of liver cancer. *Best Pract Res Clin Gastroenterol* 2005;19:91-99.
13. De Palma M, Venneri MA, Galli R, Sergi L, Politi LS, Sampaolesi M, Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell* 2005;8:211-226.
14. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. *J Immunol* 2007;178:7405-7411.
15. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. *Blood* 2007;109:5276-5285.
16. Clinical Practice Guidelines for Hepatocellular Carcinoma · The Japan Society of Hepatology 2009 update. *Hepatol Res* 2010;40 Suppl 1:2-144.
17. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. *J Clin Oncol* 2002;20:1775-1785.
18. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, Biswas SK, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. *Cancer Res* 2010;70:5270-5280.
19. Mund JA, Case J. The ontogeny of endothelial progenitor cells through flow cytometry. *Curr Opin Hematol* 2011;18:166-170.
20. Ancuta P, Liu KY, Misra V, Wacleche VS, Gosselin A, Zhou X, Gabuzda D. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. *BMC Genomics* 2009;10:403.
21. Koch S, Kucharzik T, Heidemann J, Nusrat A, Luegering A. Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease. *Clin Exp Immunol* 2010;161:332-341.
22. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zerneck A, Tischendorf JJ, et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. *PLoS One* 2010;5:e11049.
23. Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N, Akashi S, et al. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. *Arthritis Rheum* 2004;50:1457-1467.
24. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, et al. Active immunotherapy induces antibody responses that target tumor angiogenesis. *Cancer*

Res;2010;70:10150-10160.

25. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, Lee PC, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. *Eur J Surg Oncol* 2007;33:208-212.
26. Laurent J, Touvrey C, Botta F, Kuonen F, Ruegg C. Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. *Int J Dev Biol* 2011;55:527-534.
27. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, Shin JW, et al. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. *Cancer* 2002;94:175-180.
28. Talaat RM. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. *Viral Immunol* 2010;23:151-157.
29. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. *J Clin Oncol* 2008;26:2707-2716.

**Table.1: The clinical backgrounds of the subjects**

Clinicopathologic characteristics	CH	LC	HCC
Gender: Male/female	21/28	13/17	63/26
Age: mean±SD	63.4±7.8	67.5±8.8	70.0±7.0
Alanine aminotransferase (IU/L)	56.1±43.5	54.0±28.6	46.3±29.5
Prothrombin time (%)	91.5±14.8	73.4±9.7	77.7±15.4
Platelet ( $\times 10^4/\text{mm}^3$ )	15.8±5.0	8.6±3.7	11.5±5.7
Albumin (g/dl)	4.0±0.3	3.5±0.4	3.5±0.5
Total bilirubin (mg/dl)	0.7±0.3	0.9±0.4	0.9±0.6
Child-Pugh grade: A/B	49/0	21/9	59/30
$\alpha$ -fetoprotein (ng/ml)	8.7±10.7	42.6±80.6	264.0±1281.7
TNM stage: I/II/III/IV			33/37/15/4
BCLC stage: A/B/C/D			44/13/26/6

TNM, Tumor, Lymph Node and Metastasis; BCLC, Barcelona-Clinic Liver Cancer; CH, chronic hepatitis; LC, liver cirrhosis; HCC, hepatocellular carcinoma

**Table.2: The comparison of clinical parameters of HCC patients between those with higher frequency of TEMs and those with lower frequency**

Clinicopathologic characteristics	Peripheral TEMs		
	High (n=45)	Low (n=44)	P
Gender: Male/female	32/13	31/13	1.000 <sup>†</sup>
Age: mean±SD	71.4±6.6	68.7±7.3	0.065 <sup>‡</sup>
Child-Pugh grade: A/B	24/20	34/10	<b>0.043<sup>†</sup></b>
MELD score	9.1±2.3	8.2±1.8	<b>0.010<sup>§</sup></b>
α-fetoprotein (ng/ml)	471.0±1785.2	52.3±101.4	0.101 <sup>§</sup>
TNM stage: I+II/III+IV	35/10	35/9	1.000 <sup>†</sup>
BCLC stage: A+B/C+D	25/20	32/12	0.123 <sup>†</sup>
Vascular invasion: present/absent	4/41	2/42	0.677 <sup>†</sup>
Tumor size: <3/>3cm	36/9	34/10	0.800 <sup>†</sup>
Tumor number: single/multiple	21/24	25/19	0.399 <sup>†</sup>
Alanine aminotransferase (IU/L)	51.5±34.5	41.0±22.6	0.251 <sup>§</sup>
Prothrombin time (%)	73.3±14.5	82.6±15.0	<b>0.004<sup>§</sup></b>
Platelet (×10 <sup>4</sup> /mm <sup>3</sup> )	10.8±5.2	12.2±6.2	0.319 <sup>§</sup>
Albumin (g/dl)	3.4±0.4	3.6±0.6	<b>0.045<sup>§</sup></b>
Total bilirubin (mg/dl)	0.9±0.6	0.9±0.5	0.820 <sup>§</sup>

P value of less than 0.05 was expressed by thick one.

<sup>‡</sup>Student's *t* test, <sup>†</sup>χ<sup>2</sup> test or Fisher exact test, <sup>§</sup>Mann-Whitney *U* test.

TEMs, TIE2-expressing monocytes; MELD, model for endstage liver disease

**Table.3: The assessment of diagnostic value of the TEMs, AFP and PIVKA-II by ROC analyses**

Discrimination between	Parameter	AUC	Cut off value	Sensitivity (%)	Specificity (%)	Positive predictive values (%)	Negative predictive values (%)
HCC and CLD	TEMs	0.85	1.46	86.1	71	76.3	82.4
	AFP	0.69	10	65.9	43.9	65.9	56.1
	PIVKA-II	0.77	47	56.3	96.5	97.8	44.5
	ANG-2	0.62	2681	51.4	67.3	52.8	64
HCC and LC	TEMs	0.93	2.75	81.3	90	89.7	81.8
	AFP	0.61	10	71.9	32.1	54.8	50
	PIVKA-II	0.79	39	64.5	93.3	95.2	56
	ANG-2	0.57	2440	68.8	52	47.8	72.2

The optimal cut-off point was determined as those yielding the minimal value for  $(1-\text{sensitivity})^2 + (1-\text{specificity})^2$ . Such point with those sensitivity and specificity values is the closest to (0, 1) point on ROC curve.

AUC, Area under the curve; TEMs, TIE2-expressing monocytes; CLD, chronic liver disease; LC, liver cirrhosis; ANG-2, angiotensin-2



**Supplementary Table.1: The inclusion and exclusion criteria for the enrollment of patients**

---

**Eligible criteria for patients with hepatocellular carcinoma (HCC)**

---

- 1) PS: 0~2 (ECOG PS)
  - 2) Age: 40 - 80 years
  - 3) Viable HCC was diagnosed by imaging analyses, such as CT and/or MRI.  
Histological diagnosis is optional depending on the availability for tissue samples.
  - 4) De novo as well as recurrent HCC are included
  - 5) Patients who were tolerable for trans-catheter arterial chemo-embolization therapy, local ablation therapy and/or surgical resection of the tumor
- 

---

**Eligible criteria for patients with chronic liver disease**

---

- 1) PS: 0~2 (ECOG PS)
  - 2) Age: 40 - 80 years
  - 3) The presence of HCC was excluded by imaging analyses
  - 4) Chronic hepatitis or liver cirrhosis was clinically diagnosed by biochemical and imaging examinations
- 

---

**Exclusion criteria for patients**

---

- 1) Pregnant women
  - 2) Patients with bleeding tendency (%prothrombin time<50%, platelet counts<30000/mm<sup>3</sup>)
  - 3) Patients with autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis
  - 4) Patients with autoimmune diseases in any organs
  - 5) Patients whom the attending doctors determined as ineligible
- 

PS, Performance status; ECOG, Eastern Cooperative Oncology Group




Fig. 1: Identification and phenotypic analyses of TEMs as CD14+CD16+TIE2+ cells in the peripheral blood. A. PBMC obtained from HCC patients were stained and analyzed by flow cytometry. CD14+ monocytes were divided into two distinct subsets, CD14++CD16- and CD14+CD16+ cells. These cells were examined for TIE2 expression. The numbers in the histograms depict the percentages of gated cells. Representative plots from three patients are shown.

B. Frequencies of TIE2 in CD14+ monocytes were compared among two distinct subsets; CD16+ monocytes and CD16- monocytes, See Fig.1A. The bars indicate mean  $\pm$  SE of 89 patients. \*:  $p < 0.0001$  by Mann-Whitney nonparametric U test.

C. Western-blot analysis of TIE2 expression in FACS-sorted CD14+CD16+ and CD14++CD16- cells from HCC patients. As shown, the bands were TIE2 (140 kDa molecular weight) (the top panels) and those are  $\beta$ -actin (45 kDa molecular weight) (the bottom panels), respectively. The representative results of three series of experiments from 7 HCC patients are shown.

D. TEMs and TIE2- monocytes in the periphery were gated and analyzed for the expression of various molecules, as indicated in the histogram plots. The filled light gray line, black line and gray line depict the negative control, the expression of relevant markers in TEMs and TIE2- monocytes, respectively. The percentage of the marker-positive cells is shown in the histograms. The upper numbers are for TEMs and the lower ones are for TIE2- monocytes. The representative plots of six series of experiments are shown.

E. Comparative analyses of the expression of CCR4, CCR5, CX3CR1, CD40 and CD86 between TEMs and TIE2- monocytes, assessed by FACS as described above. The bars indicate mean  $\pm$  SE of six series of experiments. \*:  $p < 0.05$ , \*\*:  $p < 0.005$ , \*\*\*:  $p < 0.001$  by Mann-Whitney non-parametric U test.

254x190mm (300 x 300 DPI)




Fig. 2: Peripheral frequency of TEMs is increased in patients with HCC, with changes paralleling post therapeutic HCC recurrence.

A. Frequencies of peripheral TEMs in CD14+ monocytes are shown in four groups of HCV-positive patients; HS, CH, LC and HCC, see Table.1. \*:  $p < 0.0001$  by Kruskal-Wallis test with Dunn's multiple comparison test.

B. Frequencies of peripheral TEMs in HCC patients at different clinical TNM stages (early stage; I+II;  $n=70$ , advanced stage; III+IV;  $n=19$ ). n.s., not significant by Mann-Whitney nonparametric U test.

C. In patients who underwent RFA therapy or resection of HCC, the frequencies of TEMs in CD14+ monocytes were examined serially after confirmation of complete ablation or operation to remove HCC lesions. The bold arrows depict the time point of the RFA therapy or the operation. Both panels depict the frequencies of TEMs in patients before and after the treatment. The left panel shows the results of TEMs in patients without HCC recurrence ( $n=12$ ) as assessed by CT/MRI examinations, while the right panel shows the results in patients with HCC recurrence ( $n=5$ ), respectively. \*:  $p < 0.05$  by Paired t-test.

D. In patients with HCC who underwent RFA or the operation, the recurrence-free survival rate after the

treatment was compared between those with TEM<sub>high</sub> (frequency of TEMs  $\geq 2.75$ ; n=45) and TEM<sub>low</sub> (frequency of TEMs  $< 2.75$ ; n=44) using the Kaplan-Meier method, with the log-rank test for comparison. TEM<sub>high</sub> and TEM<sub>low</sub>, see Table 2. p = 0.047.  
190x254mm (300 x 300 DPI)

Accepted Article